⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7686703 | 0.76 | — | — | |
| SCHEMBL2801548 | 0.75 | TAAR1 (0.37) | — | |
| SCHEMBL1849789 | 0.70 | TLR8 (0.30) | — | |
| SCHEMBL1914618 | 0.68 | CYP19A1 (0.33) | — | |
| SCHEMBL114512 | 0.68 | ALDH1A1 (0.32) | — | |
| SCHEMBL1532157 | 0.67 | NOS2 (0.43) | — | |
| SCHEMBL246415 | 0.67 | CCR1 (0.39) | — | |
| SCHEMBL153957 | 0.67 | ATP4A (0.35) | — | |
| SCHEMBL2416251 | 0.67 | — | — | |
| SCHEMBL29865866 | 0.67 | CCR1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4281073-A1 | COMBINATION OF A 3-(IMIDAZOL-4-YL)-4-(AMINO)-BENZENESULFONAMIDE TEAD INHIBITOR WITH AN EGFR INHIBITOR AND/OR MEK INHIBITOR FOR USE IN THE TREATMENT OF LUNG CANCER | Ikena Oncology, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| WO-2022159986-A1 | COMBINATION OF A 3-(IMIDAZOL-4-YL)-4-(AMINO)-BENZENESULFONAMIDE TEAD INHIBITOR WITH AN EGFR INHIBITOR AND/OR MEK INHIBITOR FOR USE IN THE TREATMENT OF LUNG CANCER | Ikena Oncology, Inc. (US) | 2022-07-28 | — | — | WO | disclosed |
| EP-3668873-A1 | IMIDAZO[1,2-A]IMIDAZOL-2-ONE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS PARKINSON'S DISEASE | H. Hoffnabb-La Roche Ag (CH) | 2020-06-24 | — | — | EP | disclosed |
| EP-3642204-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2020-04-29 | — | — | EP | disclosed |
| EP-3535261-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2019-09-11 | — | — | EP | disclosed |
| WO-2019034713-A1 | IMIDAZO[1,2-A]IMIDAZOL-2-ONE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS PARKINSON'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2019-02-21 | — | — | WO | disclosed |
| WO-2018234345-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-12-27 | — | — | WO | disclosed |
| EP-2970211-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals Inc (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151106-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-8518945-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | disclosed |